tradmap

OSTX Earnings OS Therapies Inc

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$2 -$1 $0 2023 2024 2025
EPS
Net income (annual)
-$29M -$14M $0 2023 2024 2025
Net income
Return on equity (annual)
0% 236% 472% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $0 Q2 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Net income (quarterly)
-$13M -$7M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-189% 109% 407% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–15 of 15
Q2 20262026-06-30-0.202026-08-1410-Q
Q1 20262026-03-31-0.272026-05-1810-Q
Q4 2025 (derived)2025-12-31-0.402026-03-3110-K
FY 20252025-12-31-0.982026-03-3110-K
Q3 20252025-09-30-0.212025-11-1410-Q
Q2 20252025-06-30-0.192025-08-1810-Q
Q1 20252025-03-31-0.182025-05-1510-Q
Q4 2024 (derived)2024-12-31-0.592025-03-3110-K
FY 20242024-12-31-1.282025-03-3110-K
Q3 20242024-09-30-0.182024-11-1510-Q
Q2 20242024-06-30-0.262024-08-1410-Q
Q1 20242024-03-31-0.25——
FY 20232023-12-31-2.19——
Q3 20232023-09-30-0.57——
Q2 20232023-06-30-0.47——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.